Brendan Frey

Digital

pharmaphorum speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation.

News

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.